NCT05020145View on ClinicalTrials.gov

COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States

CompletedOBSERVATIONAL
Enrollment

1,277,747

Participants

Timeline

Start Date

August 25, 2021

Primary Completion Date

December 17, 2021

Study Completion Date

December 17, 2021

Conditions
ImmunocompromisedImmunosuppressedCovid-19SARS-COV-2SARS-COV-2 InfectionBreakthrough Infection
Interventions
BIOLOGICAL

BNT162b2 (Tozinameran)

Covid-19 Vaccine

Trial Locations (1)

10021

Pfizer Inc., New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY